The proclamation says Tren de Aragua "is a hybrid criminal state that is perpetrating an invasion of and predatory incursion into the United States," and so any person 14 years or older who is a Tren ...

We believe that if successful, this last set of clinical trials to complete will be pivotal to form the basis for our new drug application ... last month, the Japanese Patent Office granted ...

Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity.

Researchers have discovered that Daphne pseudomezereum (commonly known as Onishibari) contains a substance inhibiting ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...

Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...

"We are thrilled to have received Orphan Drug Designation for Batoclimab in Japan, marking an important milestone in our efforts to bring this promising treatment to patients in need," said Sean ...

Nearly every oncology drug in development in Japan is also in development in the United States and Europe according to the most recent edition of Kantar Health’s Treatment Evolution, Japan ...

Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, subcutaneous formulation, offers the potential for at-home administration, ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...